Although studies thus far have not demonstrated an increased risk profile when GLP-1 agonists are used in a population of patients with advanced MASH, there are questions about these therapies’ effect on muscle loss and whether this muscle loss might precipitate liver decompensation. Here, GCG is linked to metabolic dysfunction-associated steatohepatitis.